Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763627 | 0.83 | AR (0.50) | AR | |
| SCHEMBL3274945 | 0.81 | AR (0.49) | AR | |
| SCHEMBL3976812 | 0.78 | AR (0.51) | AR | |
| SCHEMBL5036131 | 0.76 | AR (0.44) | AR | |
| SCHEMBL2960718 | 0.75 | AR (0.43) | AR | |
| SCHEMBL1642132 | 0.75 | AR (0.49) | AR | |
| SCHEMBL29863815 | 0.74 | AR (0.51) | AR | |
| SCHEMBL13106347 | 0.74 | AR (0.51) | AR | |
| SCHEMBL8878530 | 0.73 | XDH (0.40) | AR | |
| SCHEMBL31667703 | 0.73 | TSHR (0.43) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732480-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732480-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| US-7696241-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696241-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080096954-A1 | Novel Bicyclic Compounds As Modulators of Androgen Receptor Function And Method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096954-A1 | Novel Bicyclic Compounds As Modulators of Androgen Receptor Function And Method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1722790-A4 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070004717-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004717-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| EP-1722790-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | Bristol-Myers Squibb Company (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005086735-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004717-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | AR, NR5A1, ESRRA | AR 1/4885 |
| US-20080096954-A1 | Novel Bicyclic Compounds As Modulators of Androgen Receptor Function And Method | AR, NR5A1, ESRRA | AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.